Effects of Exercise Training on Fasting Insulin, Insulin Resistance, Insulin-like Growth Factors, and Insulin-like Growth Factor Binding Proteins in Postmenopausal Breast Cancer Survivors: A Randomized Controlled Trial[1]

Adrian S. Fairey, Kerry S. Courneya,[2] Catherine J. Field, Gordon J. Bell, Lee W. Jones, and John R. Mackey

University of Alberta, Edmonton, Alberta, Canada T6G 2H9

Abstract

Insulin, insulin-like growth factors (IGFs) I and II, and IGF binding proteins (IGFBPs) 1 and 3 have been implicated in breast cancer outcomes. We conducted a randomized controlled trial to determine the physiological effects of exercise training on changes in these biological markers in postmenopausal breast cancer survivors. Fifty-three postmenopausal breast cancer survivors were randomly assigned to an exercise ($n = 25$) or control group ($n = 28$). The exercise group trained on cycle ergometers three times per week for 15 weeks. The control group did not train. End points included changes in fasting insulin, glucose, insulin resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 molar ratio between baseline and week 15. All of the statistical tests were two-sided ($\alpha = 0.05$). Fifty-two participants completed the trial. The exercise group completed 44.3 of 45 (98.4%) prescribed exercise sessions. Baseline hormone concentrations did not differ between groups except that IGF-II was higher in the exercise group ($P = 0.011$). No significant differences between groups were observed for changes in fasting insulin (+6.3 pmol/liter; $P = 0.941$), glucose (+0.09 mmol/liter; $P = 0.824$), insulin resistance (+0.4; $P = 0.247$), IGF-II (−40.7 ng/ml; $P = 0.101$), or IGFBP-1 (+1.4 ng/ml; $P = 0.774$). However, significant differences between groups were observed for changes in IGF-I (−7.4 ng/ml; $P = 0.045$), IGFBP-3 (+180.5 ng/ml; $P = 0.021$), and IGF-I:IGFBP-3 molar ratio (−0.006; $P = 0.017$). Exercise training had significant physiological effects on IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio in postmenopausal breast cancer survivors. The clinical implications of these findings remain to be defined.

Introduction

Insulin, IGF-I,[3] IGF-II, IGFBP-1, and IGFBP-3 have been implicated in breast cancer outcomes (1). Insulin exerts mitogenic effects on normal and malignant breast epithelial cells *in vitro* (2, 3), and high fasting insulin levels have been associated with distant recurrence and death in breast cancer survivors (4). IGF-I also has potent mitogenic and antiapoptotic properties in normal and malignant breast epithelial cells *in vitro*, whereas IGFBP-1 and IGFBP-3 restricts its availability and biological activity (1, 5, 6). Although the data are not consistent, high levels of IGF-I and/or low levels of IGFBP-3 have been associated with an increased risk of breast cancer (7–10) and adverse prognostic factors (4, 11, 12). Therefore, interventions that modify these biological markers may be important in breast cancer outcomes.

Research has shown that exercise training can reduce fasting insulin levels and insulin resistance in adults with and without type 2 diabetes (13–15). Exercise training has also been shown to alter IGF and IGFBPs in healthy women (16). To date, however, no study has examined the effect of exercise training on changes in insulin, insulin resistance, IGF, and IGFBP in breast cancer survivors. Therefore, we conducted a randomized controlled trial of exercise training in postmenopausal breast cancer survivors who had completed surgery, radiotherapy, and/or chemotherapy with or without current tamoxifen or arimidex use. We hypothesized that exercise training would have a physiological effect on fasting insulin. We prospectively tested this hypothesis in the Rehabilitation Exercise for Health after Breast Cancer trial (17).

Materials and Methods

Details of the method have been described (17). Brief descriptions of the setting, participants, experimental design, randomization, and exercise intervention are provided below.

Setting and Participants. The study was conducted at the Cross Cancer Institute and University of Alberta. The Alberta Cancer Board and the University of Alberta approved the study. Written informed consent was obtained for all of the procedures.

A random sample of female breast cancer survivors was obtained from the Alberta Cancer Registry, and the referring

Received 2/7/03; revised 5/2/03; accepted 5/7/03.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
[1] This study was funded by a Research Team Grant from the National Cancer Institute of Canada (NCIC) with funds from the Canadian Cancer Society (CCS) and the CCS/NCIC Sociobehavioral Cancer Research Network. A. S. F. is supported by an Izaak Walton Killam Memorial Scholarship. K. S. C. is supported by an Investigator Award from the Canadian Institutes of Health Research.
[2] To whom requests for reprints should be addressed, at Faculty of Physical Education, University of Alberta, E-424 Van Vliet Center, Edmonton, Alberta, Canada, T6G 2H9. Phone: (780) 492-1031; Fax: (780) 492-2364; E-mail: kerry.courneya@ualberta.ca.

[3] The abbreviations used are: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; CI, confidence interval.

physician was contacted for approval. A recruitment letter was mailed to each approved survivor who then contacted the project director by telephone if interested. An exercise test and blood collection was scheduled at that time. Eligibility criteria included: (*a*) histologically confirmed stage I to IIIB breast cancer; (*b*) diagnosed between January 1999 and June 2000; (*c*) completed surgery, radiotherapy, and/or chemotherapy (≥6 months before randomization) with or without current tamoxifen or arimidex therapy; (*d*) postmenopausal (not experiencing menstrual periods for previous 12 months); (*e*) nonsmokers (not smoking for previous 12 months); (*f*) between 50 and 69 years of age; (*g*) English-speaking; and (*h*) willing to travel to the exercise facility. Eligible participants were not admitted if they had: (*a*) known cardiac disease; (*b*) uncontrolled hypertension; (*c*) uncontrolled thyroid disease; (*d*) diabetes; (*e*) mental illness; (*f*) infection; (*g*) immune or endocrine abnormality; (*h*) body weight reduction ≥10% in past 6 months; or (*i*) positive exercise stress test.

Experimental Design and Randomization. The study was a prospective, randomized controlled trial. Participants were stratified by type of adjuvant therapy (previous chemotherapy *versus* no previous chemotherapy and current hormone therapy use *versus* no current hormone therapy use) and block randomized to an exercise or control group using a random-numbers table. A research assistant generated the allocation sequence, and the project director assigned participants to groups.

Exercise Training Intervention. The exercise training intervention was designed to improve cardiopulmonary fitness and was based on the fitness level of each participant at baseline. The exercise group trained three times per week for 15 weeks on recumbent or upright cycle ergometers (Lifestyle Fitness 9500HR; Lifecycle Inc.). Exercise intensity was set at the power output that elicited the ventilatory equivalent for carbon dioxide (~70–75% of peak oxygen consumption). Exercise duration began at 15 min for weeks 1–3, and then systematically increased by 5 min every 3 weeks thereafter to 35 min for weeks 13–15. Warm-up and cool-down periods consisted of 5 min of cycling at the power output that elicited the ventilatory equivalent for oxygen (~50% of peak oxygen consumption). Exercise physiologists supervised the exercise sessions, and monitored heart rate and blood pressure. The control group did not train, and were asked not to begin a structured exercise program. To reduce attrition, the control group was offered the intervention after the trial.

Several strategies were used to promote adherence to the exercise training intervention. These included individualized attention at the exercise facility, telephone calls to reschedule missed sessions, individual meetings to outline goals and provide feedback on progress, and the opportunity to exercise alone or in a small group.

End Points and Blinding. End points included changes in fasting insulin, glucose, insulin resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 molar ratio between baseline and week 15. Laboratory staff and those who assessed the study end points were blinded to treatment assignment.

Blood Collection. Participants were instructed not to exercise for at least 48 h before blood collection. Blood was collected between 7:00 a.m. and 10:00 a.m. after a 12-h water-only fast with participants in the seated position. Blood was drawn into tubes chilled on ice treated with sodium heparin (for plasma) or no anticoagulant (for serum). Blood was centrifuged at 700 × *g* at 23°C for 10 min. Plasma and serum were aliquoted and stored at −70°C. Precautions were taken to prevent thawing or warming of specimens during storage. Blood samples were collected from 53 participants at baseline and 52 participants at week 15.

Laboratory Analyses and Calculations. Insulin was measured in plasma using a radioimmunoassay kit (Count-A-Count; DPC, Los Angeles, CA). Glucose was measured in plasma using a glucose analyzer (Beckman Instruments, Brea, CA). IGF-I and IGFBP-3 were measured in plasma using ELISA kits (Quantikine; R & D Systems, Inc., Minneapolis, MN). IGF-II and IGFBP-1 were measured in serum using ELISA kits (Diagnostic Systems Laboratories, Inc., Webster, TX). All of the samples were analyzed by using assay kits from a single lot before the expiration date of the assay kit. Each assay was performed in one batch (*i.e.*, baseline and week 15 assessments of each analyte for both exercise and control group participants were performed in one batch). Duplicate measurements were made for each sample, and the mean of the duplicate measurements was assigned as the sample value. Blind duplicates were used for determining coefficients of variation. The mean intra-assay coefficient of variation was 1.6% for insulin, 5.1% for IGF-I, 4.4% for IGF-II, 6.3% for IGFBP-1, and 3.0% for IGFBP-3.

Insulin resistance was estimated by homeostatic model assessment (18). It was calculated as the product of the fasting plasma insulin level (in microunits per milliliter) and the fasting glucose level (in millimoles per liter), divided by 22.5. The IGF-I:IGFBP-3 molar ratio was calculated as the fasting plasma IGF-I level divided by the fasting plasma IGFBP-3 level.

Baseline Characteristics. Demographic data were collected by self-report. Medical data were abstracted from medical records.

Dietary Intake and Daily Medication Use. Dietary intake was assessed using 3-day diet records. Participants completed the 3-day diet records on consecutive days before blood collection at baseline. These records were photocopied and returned to participants at week 15. Participants were asked to consume the same diet on the 3 consecutive days before blood collection at week 15. No specific diet was prescribed. Diet records were analyzed using the Food Processor II program (ESHA Research, Salem, OR). Daily medication use in the 6 months before the intervention and during the intervention period was assessed by self-report.

Adherence to the Exercise Training Intervention. Exercise levels outside of the exercise intervention were assessed using the leisure score index of the Godin Leisure-Time Exercise Questionnaire (19). Participants completed the leisure score index on a biweekly basis during the intervention period. The exercise physiologists monitored adherence to the intervention.

Statistical Analysis. Data were analyzed using the intention-to-treat approach with SPSS version 10.0 software (SPSS, Inc., Evanston, IL). The last-observation-carried-forward procedure was used for participants who did not complete the trial. Therefore, if data were missing at week 15, we assumed that there was a return to the baseline value. Distributions were checked for skewness and outliers. This led to the following transformations in statistical analyses: glucose (inverse) and insulin (log). These transformations were reversed for presentation of data.

Baseline comparisons between the two groups were made using independent-samples *t* tests for continuous data and Pearson's χ^2 tests for categorical data. The primary analysis used independent-samples *t* tests to compare changes between groups in end points from baseline to week 15. Change over the intervention period was calculated by subtracting the baseline value from the week 15 value. A two-sided $P < 0.05$ indicated



Fig. 1. Flow of participants through the trial. Adapted from Courneya *et al.*, J. Clin. Oncol. *21:*1660–1668, 2003 with permission from the American Society of Clinical Oncology.

statistical significance. No adjustments were made for multiple comparisons. Data are presented as the mean (±SD) with 95% CIs.

Results

Flow of Participants Through the Trial. Fig. 1 shows the flow of participants through the trial. In brief, 370 breast cancer survivors were assessed for eligibility during the recruitment period, and 53 (14.3%) were randomly assigned to the exercise ($n = 25$) or control group ($n = 28$). During the intervention period, 1 participant (4.2%) dropped out in the exercise group compared with 0 participants in the control group ($P = 0.285$). Overall, 52 of 53 participants completed the trial (98.1%).

Baseline Characteristics. Table 1 presents the baseline characteristics. The groups were balanced in terms of demographic, medical, and past exercise variables.

Diet Intake and Daily Medication Use. Table 2 shows information on dietary intake and daily medication use. The groups were balanced in terms of dietary intake and daily medication use variables except that there were trends toward a difference between groups for use of acetaminophen ($P = 0.054$) and thyroid hormone ($P = 0.054$).

Adherence to the Intervention. The exercise group completed 44.3 of 45 (98.4%) of the prescribed exercise sessions. Nonprotocol-related exercise was low and did not differ between groups ($P = 0.890$). The exercise group reported an average of 15 min of moderate/strenuous nonprotocol-related exercise per week compared with 13 min in the control group.

Changes in Cardiopulmonary Fitness and Body Composition. Changes in cardiopulmonary fitness and body composition have been described (17). In brief, baseline values for peak oxygen consumption ($P = 0.254$), body weight ($P = 0.983$), body mass index ($P = 0.725$), and sum of skinfolds ($P = 0.650$) did not differ between groups. A significant difference between groups was observed for change in peak oxygen consumption (mean difference, +0.29 liters/min; 95% CI, 0.18–0.40 liters/min; $P < 0.001$). No significant differences between groups were observed for changes in body weight (mean difference,

Table 1 Baseline Characteristics[a]

Variable	Overall (n = 52)	Exercise group (n = 24)	Control group (n = 28)	P[b]
Demographic				
Age (years)	59 (6)	59 (5)	58 (6)	0.712
Medical				
Weight (kg)	78.7 (18.1)	78.1 (20.4)	79.4 (16.4)	0.801
Body mass index (kg/m^2)	29.2 (6.6)	29.4 (7.4)	29.1 (6.1)	0.880
Months postsurgery, RT, and/or CT[c]	14 (6)	14 (6)	14 (7)	0.856
Stage				
I (T_1N_0)	21 (40%)	10 (42%)	11 (39%)	0.862
IIa (T_1N_1, T_2N_0)	17 (33%)	6 (25%)	11 (39%)	0.274
IIb (T_2N_1, T_3N_0)	11 (21%)	6 (25%)	5 (18%)	0.530
IIIa (T_1N_2, T_2N_2, T_3N_{1-2})	3 (6%)	2 (8%)	1 (4%)	0.463
Surgery				
Mastectomy	28 (54%)	15 (64%)	13 (46%)	0.246
Lumpectomy	24 (46%)	9 (37%)	15 (54%)	0.246
Radiation therapy	37 (71%)	16 (67%)	21 (75%)	0.508
Chemotherapy	21 (40%)	10 (42%)	11 (39%)	0.862
Anthracycline regimen	20 (38%)	10 (42%)	10 (36%)	0.329
Current hormone therapy use	24 (46%)	11 (46%)	13 (46%)	0.966
Past exercise				
Moderate minutes	82 (114)	62 (94)	98 (126)	0.247
Strenuous minutes	25 (61)	23 (56)	26 (65)	0.897
Moderate/strenuous minutes	106 (129)	85 (102)	124 (146)	0.280
>90 Moderate/strenuous	22 (42%)	10 (42%)	12 (42.9%)	0.931

Data are presented as the mean (SD) for continuous variables and frequency (percentage) for categorical variables.
[a] Adapted with permission from Ref. 17.
[b] P for difference between groups.
[c] RT, radiation therapy; CT, chemotherapy.

−0.6 kg; 95% CI, −1.6 to +0.6 kg; P = 0.339) or body mass index (mean difference, −0.3 kg/m^2; 95% CI, −0.6 to +0.3 kg/m^2; P = 0.337) but there was a trend toward a change in sum of skinfolds (mean difference, −10.2 mm; 95% CI, −21.6 to +1.8 mm; P = 0.095).

Changes in Insulin, Glucose, Insulin Resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 Molar Ratio. Table 3 presents the hormone end points. Baseline concentrations did not differ between groups except that IGF-II was higher in the exercise group (P = 0.011). No significant differences between groups were observed for changes in fasting insulin (mean difference, +6.3 pmol/liter; 95% CI, −6.1 to +18.8 pmol/liter; P = 0.941), glucose (mean difference, +0.09 mmol/liter; 95% CI, −0.3 to +0.5 mmol/liter; P = 0.824), insulin resistance (mean difference, +0.4; 95% CI, −0.3 to +1.0; P = 0.247), IGF-II (mean difference, −40.7 ng/ml; 95% CI, −89.7 to +8.3 ng/ml; P = 0.101), and IGFBP-1 (mean difference, +1.4 ng/ml; 95% CI, −8.6 to +11.5 ng/ml; P = 0.774). However, significant differences between groups were observed for changes in IGF-I (mean difference, −7.4 ng/ml; 95% CI, −14.6 to −0.2 ng/ml; P = 0.045), IGFBP-3 (mean difference, +180.5 ng/ml; 95% CI, +28.4 to +332.5 ng/ml; P = 0.021), and IGF-I:IGFBP-3 molar ratio (mean difference, −0.006; 95% CI, −0.01 to −0.001; P = 0.017).

Discussion

The Rehabilitation Exercise for Health after Breast Cancer trial is the first study to evaluate the physiological effects of exercise training on fasting insulin, glucose, insulin resistance, IGF, and IGFBP in cancer survivors. We found that exercise training had no significant physiological effects on fasting insulin, glucose, insulin resistance, IGF-II, and IGFBP-1 in postmenopausal breast cancer survivors. However, exercise training did have significant physiological effects on IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio.

The strengths and limitations of our data merit consideration. Strengths include the randomized controlled trial design, standardized blood collection protocols, high exercise adherence rate, and minimal loss to follow-up. Limitations include the 14% recruitment rate, small sample size, short exercise intervention with no long-term follow-up, and use of a single hormone measurement to classify participants.

Key findings of our trial were that exercise training had no significant physiological effect on fasting insulin, glucose, or insulin resistance in postmenopausal breast cancer survivors. These results are in contrast to previous observations. In a randomized controlled trial, Ross *et al.* (13) demonstrated that 3 months of exercise-induced weight loss (700 kcal/day, ≤70% of peak oxygen consumption) improved insulin sensitivity by ~60% in obese men. In a nonrandomized trial, Duncan *et al.* (15) showed that 6 months of exercise training without weight loss (3–7 sessions/week, 45–75% of heart rate reserve, 30 min/session) improved insulin sensitivity by ~70% in overweight, sedentary adults. Finally, in a meta-analysis of controlled clinical trials, Boule *et al.* (20) showed that aerobic (3.4 sessions/week, 18 weeks) or resistance (10 exercises, 2.5 sets, 13 repetitions, 2.5 times/week, 15 weeks) exercise training reduced glycosylated hemoglobin (HbA_{1C}) by 0.66% in adults with type 2 diabetes mellitus.

There are several possible explanations for the lack of effects on fasting insulin, glucose, and insulin resistance in our trial. First, our exercise training intervention did not induce weight loss, which is known to reverse the hyperinsulinemia and insulin resistance that is associated with overweight and obesity (13, 21, 22). However, exercise training does not necessarily need to reduce body weight to have beneficial physiological effects on insulin resistance and glycemic control (13,

Table 2 Dietary intake and daily medication use[a]

Variable	Overall (n = 52)	Exercise group (n = 24)	Control group (n = 28)	P[b]
Dietary intake				
Total calories (Kcal/day)	1780 (389)	1782 (391)	1779 (395)	0.979
Percent calories from fat	33 (6)	34 (5)	32 (7)	0.288
Percent calories from carbohydrates	50 (8)	49 (6)	51 (8)	0.253
Percent calories from protein	16 (3)	16 (3)	16 (4)	0.440
Total fat (g)	59 (15)	60 (14)	58 (17)	0.541
Total carbohydrate (g)	228 (61)	220 (54)	234 (67)	0.428
Total protein (g)	73 (23)	74 (21)	71 (25)	0.663
Daily medication use				
ACE inhibitor	3 (5%)	1 (4%)	2 (7%)	0.646
Acetaminophen	3 (5%)	3 (13%)	0 (0%)	0.054
α-Antagonist	2 (4%)	2 (8%)	0 (0%)	0.119
Antibiotic	1 (2%)	0 (0%)	1 (4%)	0.350
Antifungal	1 (2%)	0 (0%)	1 (4%)	0.350
Anti-inflammatory	15 (29%)	7 (29%)	8 (29%)	0.962
Aspirin	3 (5%)	2 (8%)	1 (4%)	0.463
Atorvastatin	3 (5%)	1 (4%)	2 (7%)	0.646
β-Blocker	1 (2%)	0 (0%)	1 (4%)	0.350
Bisphosphonate	11 (19%)	7 (29%)	4 (14%)	0.190
Calcium channel blocker	1 (2%)	1 (4%)	1 (4%)	0.911
Diuretic	2 (4%)	1 (4%)	1 (4%)	0.911
Hormone replacement therapy	1 (2%)	0 (0%)	1 (4%)	0.350
Hydrogen ion blocker	1 (2%)	0 (0%)	1 (4%)	0.350
Leukotriene antagonist	1 (2%)	1 (4%)	0 (0%)	0.275
Nasal steroid	2 (4%)	1 (4%)	1 (4%)	0.911
Proton pump inhibitor	4 (7%)	3 (13%)	1 (4%)	0.228
Sedative	6 (12%)	4 (17%)	2 (7%)	0.284
Selective serotonin reuptake inhibitor	11 (19%)	6 (25%)	5 (18%)	0.530
Sumatriptan	1 (2%)	1 (4%)	0 (0%)	0.275
Thyroid hormone	13 (23%)	3 (13%)	10 (36%)	0.054
Ventolin	1 (2%)	0 (0%)	1 (4%)	0.350

[a] Data are presented as the mean (SD) for continuous variables and frequency (percentage) for categorical variables.
[b] P for the difference between groups.

21). Second, blood collection was performed after a period of at least 48 h without exercise. Given that it is known that acute exercise is associated with substantial improvements in insulin resistance when measured within 48 h of the last exercise session (23, 24), it is likely that the short-term effects of exercise on insulin resistance had dissipated. Third, the sample size of our trial may have been too small to detect a treatment effect.

Other findings of our trial were that exercise training did have significant physiological effects on IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio. Previous trials of exercise training and IGF-I and IGFBP-3 in older women have reported mixed results (16, 25–32), making it difficult to compare our findings. However, comparison of our effects with those reported in trials of selective estrogen receptor modulator therapies is instructive. The direction and magnitude of the between-group change in IGF-I (10.9%) and IGF-I:IGFBP-3 molar ratio (18.2%) in our trial is similar to that observed in a randomized controlled trial of raloxifene in postmenopausal breast cancer survivors (33). In this trial, participants were assigned to receive 600 mg/day of raloxifene, 60 mg/day of raloxifene, or placebo for 14 days. Comparison of participants assigned to 600 mg/day of raloxifene with those assigned to placebo revealed significant between-group changes in IGF-I and IGF-I:IGFBP-3 molar ratio of 15 and 20%, respectively (33). However, nonrandomized breast cancer trials of selective estrogen receptor modulator therapies such as tamoxifen (34–37) and droloxifene (38) have reported decreases in IGF-I between 20 and 40%. Reasons for these differences in magnitude of the effect remain to be determined but may include both the dose and length of drug administration. The between-group change in IGFBP-3 (8.4%) that we observed has not been demonstrated in three previous trials of anticancer drug therapies (12, 33, 38) but is consistent with one recent prospective cohort study of tamoxifen in postmenopausal breast cancer survivors (34). Therefore, in aggregate, these data suggest that exercise training may provide similar physiological effects on IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio compared with selective estrogen receptor modulator therapies.

Exercise-induced modulation of fasting insulin, glucose, insulin resistance, IGF, and IGFBP is biologically plausible. Exercise training may decrease hepatic and muscle insulin resistance, and increase glucose disposal by a number of mechanisms including increased postreceptor insulin signaling, increased glucose transporter protein and mRNA, increased activity of glycogen synthase and hexokinase, decreased release and increased clearance of free fatty acids, increased muscle glucose delivery because of increased muscle capillary density, and changes in muscle composition favoring increased glucose disposal (39). This reduction in insulin resistance may lower circulating levels of insulin (24), which, in turn, may decrease IGF bioavailability via insulin-mediated changes in IGFBP concentrations. Although our findings do not provide evidence of these mechanisms and other factors may be involved (40, 41), these effects may represent clinically significant biological mechanisms of action of exercise training.

Additional studies designed to evaluate the effects of exercise training on changes in fasting insulin, glucose, insulin

Table 3 Changes in insulin, glucose, insulin resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 molar ratio[a]

End point	Baseline	P[b]	Week 15	Mean change	Difference between groups in mean change (95% CI)	P value[c]
Insulin (pmol/liter)						
Exercise group (n = 25)	60.2 (34.8)		67.5 (51.9)	+7.2 (26.0)		
Control group (n = 28)	53.2 (36.3)	0.381	54.1 (37.3)	+0.9 (18.8)	+6.3 [−6.1 to 18.8]	0.941
Glucose (mmol/liter)						
Exercise group (n = 25)	5.9 (1.5)		5.8 (1.7)	−0.07 (1.0)		
Control group (n = 28)	5.5 (0.8)	0.255	5.4 (0.9)	−0.16 (0.5)	+0.09 [−0.3 to 0.5]	0.824
Insulin resistance index						
Exercise group (n = 25)	2.3 (2.1)		2.7 (3.0)	+0.4 (1.4)		
Control group (n = 28)	1.9 (1.7)	0.424	1.9 (1.9)	0.0 (0.9)	+0.4 [−0.3 to 1.0]	0.247
IGF-I (ng/ml)						
Exercise group (n = 25)	67.4 (29.1)		62.5 (23.9)	−4.9 (10.7)		
Control group (n = 28)	70.0 (21.5)	0.705	72.6 (24.8)	+2.5 (14.8)	−7.4 [−14.6 to −0.2]	0.045
IGF-II (ng/ml)						
Exercise group (n = 25)	824.9 (155.5)		805.0 (139.9)	−19.9 (97.1)		
Control group (n = 28)	714.5 (148.9)	0.011	735.3 (152.4)	+20.9 (80.5)	−40.7 [−89.7 to 8.3]	0.101
IGFBP-1 (ng/ml)						
Exercise group (n = 25)	47.5 (32.3)		53.2 (30.4)	+5.6 (13.4)		
Control group (n = 28)	48.2 (29.8)	0.933	52.4 (34.2)	+4.2 (21.2)	+1.4 [−8.6 to 11.5]	0.774
IGFBP-3 (ng/ml)						
Exercise group (n = 25)	2160.8 (421.1)		2264.2 (435.4)	+103.4 (224.7)		
Control group (n = 28)	2146.2 (438.2)	0.902	2069.1 (478.4)	−77.1 (313.5)	+180.5 [28.4 to 332.5]	0.021
IGF-I:IGFBP-3 molar ratio						
Exercise group (n = 25)	0.032 (.013)		.028 (0.012)	−0.003 (0.006)		
Control group (n = 28)	0.034 (.015)	0.518	.037 (0.015)	+0.003 (0.01)	−0.006 [−0.01 to −0.001]	0.017

[a] Data are presented as the mean (SD).
[b] P for independent t tests comparing the exercise group and control group at baseline.
[c] P for independent t tests comparing changes between the exercise group and control group from baseline to week 15.

resistance, IGF, and IGFBP in postmenopausal breast cancer survivors are needed. Researchers should attempt to confirm our findings in a larger sample of survivors and determine whether there are differential physiological effects to be achieved by altering the exercise parameters (frequency, intensity, time, and type). Studies are also needed to test underlying biological mechanisms of action and to evaluate whether exercise-induced modulation of fasting insulin, glucose, insulin resistance, IGF, and IGFBP is associated with breast cancer outcomes.

In summary, exercise training had no significant physiological effects on fasting insulin, glucose, insulin resistance, IGF-II, and IGFBP-1 in postmenopausal breast cancer survivors. However, exercise training did have significant physiological effects on IGF-I, IGFBP-3, and IGF-I:IGFBP-3 molar ratio. The clinical implication(s) of our findings remain to be defined.

Acknowledgments

We thank Dr. Christine Friedenreich for assistance with the literature review. We also thank Susan Goruk, Dr. Isabelle Vonder Muhll, Dr. Lise Warmington, Neil Eves, John McGavock, Blair St. Martin, and Kristin Campbell for assistance in assessment and data management.

References

1. Yu, H., and Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., *92:* 1472–1489, 2000.

2. Belfiore, A., Frittitta, L., Costantino, A., Frasca, F., Pandini, G., Sciacca, L., Goldfine, I. D., and Vigneri, R. Insulin receptors in breast cancer. Ann. N. Y. Acad. Sci., *784:* 173–188, 1996.

3. Papa, V., and Belfiore, A. Insulin receptors in breast cancer: biological and clinical role. J. Endocrinol. Investig., *19:* 324–333, 1999.

4. Goodwin, P. J., Ennis, M., Pritchard, K., Trudeau, M. E., Koo, J., Madarnas, Y., Hartwick, W., Hoffman, B., and Hood, N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol., *20:* 42–51, 2002.

5. Le Roith, D. Insulin-like growth factors. N. Engl. J. Med., *336:* 633–640, 1997.

6. Lee A. V., and Lee D. Role of the IGF system in breast cancer proliferation and progression. *In:* A. Manni (ed.), Endocrinology of Breast Cancer, pp. 187–203. Totowa, NJ: Humana Press, 1999.

7. Peyrat, J. P., Bonneterre, J., Hecquet, B., Vennin, P., Louchez, M. M., Fournier, C., Lefebvre, J., and Demaille, A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer, *29A:* 492–497, 1993.

8. Bruning, P. F., Van Doorn, J., Bonfrer, J. M. G., Van Noord, P. A., Korse, C. M., Linders, T. C., and Hart, A. A. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int. J. Cancer, *62:* 266–270, 1995.

9. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, *351:* 1393–1396, 1998.

10. Bohlke, K., Cramer, D. W., Trichopoulos, D., and Mantzoros, C. S. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma *in situ* of the breast. Epidemiology, *9:* 570–573, 1998.

11. Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Hartwick, W., Hoffma, B., and Hood, N. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res. Treat., *74:* 65–76, 2002.

12. Vadgama, J. V., Yanyuan, W., Geetanjali, D., Khan, H., and Chillar, R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in african-american and hispanic women. Oncology, *57:* 330–340, 1999.

13. Ross, R., Dagnone, D., Jones, P. J., Smith, H., Paddags, A., Hudson, R., and Janssen, I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise–induced weight loss in men. A randomized, controlled trial. Ann. Intern. Med., *133:* 92–103, 2000.

14. Evans., E. M., Van Pelt., R. E., Binder, E. F., Williams, D. B., Ehsami, A. A., and Kohrt, W. M. Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women. J. Appl. Physiol., *90:* 2033–2040, 2001.

15. Duncan, G. E., Perri, M. G., Theriaque, D. W., Hutson, A. D., Eckel, R. H., and Stacpoole, P. W. Exercise training, without weight loss, increases insulin sensitivity and postherapin plasma lipase activity in previously sedentary adults. Diabetes Care, *26:* 557–562, 2003.

16. Schmitz, K. H., Ahmed, R. L., and Yee, D. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-1, and IGFBP-3 in 30–50-year-old women. Cancer Epidemiol. Biomark. Prev., *11:* 1597–604, 2002.

17. Courneya, K. S., Mackey, J. R., Bell, G. J., Jones, L. W., Field, C. J., and Fairey, A. S. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J. Clin. Oncol., *21:* 1660–1668, 2003.

18. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, *28:* 412–419, 1985.

19. Godin, G., and Shephard, R. J. A. simple method to assess exercise behavior in the community. Can. J. Appl. Sport Sci., *10:* 141–146, 1985.

20. Boule, N. G., Haddad, E., Kenny, G. P., Wells, G. A., and Sigal, R. J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trails. JAMA, *286:* 1218–1227, 2001.

21. Goodpaster, B. H., Kelley, D. E., Wing, R. R., Meier, A., and Thaete, F. L. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes, *48:* 839–847, 1999.

22. Niskanen, L., Uusitupa, M., Sarlund, H., Siitonen, O., Paljarvi, L., and Laakso, M. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int. J. Obes. Relat. Metab. Disord., *20:* 154–160, 1996.

23. Perseghin, G., Price, T. B., Petersen, K. F., Roden, M., Cline, G. W., Gerow, K., Rothman, D. L., and Shulman, G. I. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N. Engl. J. Med., *225:* 1357–1362, 1996.

24. Goodyear, L. J., and Kahn, B. B. Exercise, glucose transport, and insulin sensitivity. Ann. Rev. Med., *49:* 235–261, 1998.

25. Kohrt, W. M., Snead, D. B., Slatopolsky, E., and Birge, S. J., Jr. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J. Bone Miner. Res., *10:* 1303–1311, 1995.

26. Parkhouse, W. S., Coupland, D. C., Li, C., and Vanderhoek K. J. IGF-1 bioavailability is increased by resistance training in older women with low bone mineral density. Mech. Ageing Dev., *113:* 75–83, 2000.

27. Hakkinen, K., Pakarinen, A., Kraemer, W. J., Hakkinen, A., Valkeinen, H., and Alen, M. Selective muscle hypertrophy, changes in EMG and force, and serum hormones during strength training in older women. J. Appl. Physiol., *91:* 569–580, 2001.

28. Poehlman, E. T., Rosen, C. J., and Copeland, K. C. The influence of endurance training on insulin-like growth factor-1 in older individuals. Metabolism, *43:* 1401–1405, 1994.

29. Vitiello, M. V., Wilkinson, C. W., Merriam, G. R., Moe, K. E., Prinz, P. N., Ralph, D. D., Colasurdo E. A., and Schwartz R. S. Successful 6-month endurance training does not alter insulin-like growth factor-I in healthy older men and women. J. Gerontol. A Biol. Sci. Med. Sci., *52:* M149–M154, 1997.

30. Maddalozzo, G. F., and Snow, C. M. High intensity resistance training: effects on bone in older men and women. Calcify Tissue Int., *66:* 399–404, 2000.

31. Lange, K. H., Lorentsen, J., Isaksson, F., Juul, A., Rasmussen, M. H., Christensen, N. J., Bulow, J., and Kjaer, M. Endurance training and GH administration in elderly women: effects on abdominal adipose tissue lipolysis. Am. J. Physiol. Endocrinol. Metab., *280:* E886–E897, 2001.

32. Borst, S. E., Vincent, K. R., Lowenthal, D. T., and Braith, R. W. Effects of resistance training on insulin-like growth factor and its binding proteins in men and women aged 60 to 85. J. Am. Geriatr. Soc., *50:* 884–888, 2002.

33. Torrisl, R., Baglietto, L., Johansson, H., *et al.* Effect of raloxifene on IGF-1 and IGFBP-3 in postmenopausal women with breast cancer. Br. J. Cancer, *85:* 1838–1841, 2001.

34. Ho, H. G., Ji, C. Y., Phang, B. H., Lee, K. C., and Ng, E. H. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann. Surg. Oncol., *5:* 361–367, 1988.

35. Lonning, P. E., Hall, K., Aakvaag, A., and Kien, E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-1 in breast cancer patients. Cancer Res., *52:* 4719–4723, 1992.

36. Pollak, M., Constantino, J., Polychronakos, C., Blauer, S. A., Guyda, H., Redmond, C., Fisher, B., and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst., *82:* 1693–1697, 1990.

37. Lien, E. A., Johannessen, D. C., Aakvaag, A., and Lonning, P. E. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J. Steroid Biochem. Mol. Biol., *41:* 541–543, 1992.

38. Helle, S. I., Anker, G. B., Tally, M., Hall, K., and Lonning, P. E. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J. Steroid Biochem. Mol. Biol., *57:* 167–171, 1996.

39. Ivy, J. L., Zderic, T. W., and Fogt, D. L. Prevention and treatment on non-insulin-dependent diabetes mellitus. Exerc. Sport Sci. Rev., *27:* 1–35, 1999.

40. Chlebowski, R. T., Aiello, E., and McTiernan, A. Weight loss in breast cancer management. J. Clin. Oncol., *20:* 1128–1143, 2002.

41. Scheett, T. P., Milles, P. J., Ziegler, M. G., Stoppani, J., and Cooper, D. M. Effect of exercise on cytokines and growth mediators in prepubertal children. Pediatr. Res., *46:* 429–434, 1999.

Effects of Exercise Training on Fasting Insulin, Insulin Resistance, Insulin-like Growth Factors, and Insulin-like Growth Factor Binding Proteins in Postmenopausal Breast Cancer Survivors: A Randomized Controlled Trial

Adrian S. Fairey, Kerry S. Courneya, Catherine J. Field, et al.

Cancer Epidemiol Biomarkers Prev 2003;12:721-727.